Clinical Services
While survivorship is a core part of our mission, you don’t have to have had cancer to receive care here. The Brain Wellness Project is the clinical heart of our work where science, compassion, and personalized care come together.
Our team uses advanced baseline assessments to guide treatment planning and track progress over time, ensuring that every patient receives care that is both individualized and data‑driven.
Personalized Assessment
Brain mapping and function testing to guide your care
For Clinicians & Partners
Research Basis
Our approach is grounded in years of clinical research with more than 550 cancer survivors at a major cancer center in Houston. We studied how treatment affects the brain and nervous system—especially symptoms like neuropathy, fatigue, and chemotherapy-related cognitive impairment. These insights now shape every part of our care model, from assessment to therapy.
Our Methods
We employ quantitative electroencephalography (qEEG), patient-reported outcomes, and standardized functional assessments to characterize neurocognitive and neurosensory status in survivors. These baseline measures inform individualized neuromodulation protocols, which utilize non‑invasive stimulation techniques to promote neuroplasticity and optimize central nervous system function. All interventions are delivered within a structured framework that emphasizes reproducibility, safety, and translational relevance.
Outcomes and Impact
Clinical data from survivorship cohorts demonstrates measurable improvements in chemotherapy‑induced peripheral neuropathy, cognitive performance, physical functioning and affective regulation following neuromodulation interventions. Longitudinal tracking shows sustained benefit across multiple domains of quality of life. In addition, equity‑focused initiatives have expanded access to underserved populations, supporting broader dissemination and implementation of evidence‑based neurotherapeutic care. Selected references: Prinsloo, S., Novy, D., Driver, L., Lyle, R., Ramondetta, L., Eng, C., McQuade, J., Lopez, G., & Cohen, L. Randomized Controlled Trial of Neurofeedback on Chemotherapy‑Induced Peripheral Neuropathy: A Pilot Study. Cancer, 2017; 123(11):1989–1997. – Demonstrated that EEG‑based neurofeedback significantly reduced CIPN symptoms compared to controls. Prinsloo, S., et al. Neurofeedback for Chemotherapy‑Induced Peripheral Neuropathy: Results from a Randomized Clinical Trial. Cancer, 2023. – Reported robust evidence that neurofeedback interventions improved pain, sensory function, and quality of life in survivors with CIPN. Prinsloo, S., et al. Long‑Term Impact of Neurofeedback on Chemotherapy‑Induced Peripheral Neuropathy. Supportive Care in Cancer, 2024. – Showed sustained improvements in neuropathy symptoms and functional outcomes over extended follow‑up, supporting durability of neuromodulation benefits.